The Allen Institute for Cell Science has launched the first predictive and comprehensive, 3D model of a live human cell.
For the first time, scientists have revealed the essential genes for the most deadly human malaria parasite, Plasmodium falciparum. They have created new genomic techniques to analyse every gene in the parasite and determine which ones are indispensable.
Scientists have shown that boosting cells’ ability to process misfolded proteins could keep them from aggregating inside the cell, significantly delaying the onset of blindness in mice.
Researchers have created tools that would enable real-time activation of target genes in specific locations in the genome.
The link between cancer mutations and DNA repair mechanisms has been well established. However, the specific origins of the mutation in these essential pathways have remained enigmatic. Now, researchers have used human and worm data to explore the mutational causes of cancer.
At a discussion of epidemics, Bill Gates revealed that he believes the next deadly disease that will cause a global pandemic is coming, and we should prepare for it like war.
Gilead Sciences will partner with Google Parent Alphabet’s Verily Life Sciences over the next three years, applying Verily’s Immunoscape platform to better understand the immunological basis of three common diseases.
Researchers have identified a protein critical for the aggressiveness of T-cell leukaemia, a subtype of leukaemia that afflicts children and adults.
An FDA-approved drug originally designed to treat cancer may be an unlikely potential ally in the global fight against tuberculosis, a new study suggests.
Forget about the double helix – now, researchers have identified the existence of a new DNA structure that could play a crucial role in how DNA is expressed.
BD Bioscience today launched a new cloud-based system called ‘BD Synapsys Microbiology Informatics Solution’ to facilitate faster diagnostic results and improve infectious disease management.
A new study documents, for the first time, how the ability of bacteria to swap genetic material with each other can directly affect the emergence and spread of globally important infectious diseases.
General Electric aims to build on its existing expertise in biotech manufacturing by delivering a “factory-in-a-box” service specifically for viral vector-based medicine.